Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: Report of the 10th annual conference of the European Mantle Cell Lymphoma Network

Leukemia and Lymphoma

Volumn 52, Issue 12, 2011, Pages 2226-2236

  Dreyling, Martin ^a   Kluin Nelemans, Hanneke C ^b   Be, Slvia ^c   Hartmann, Elena ^d   Salaverria, Itziar ^e   Hutter, Grit ^f   Perez Galan, Patricia ^c   Roue, Gael ^c   Pott, Christiane ^e   Gouill, Steven Le ^g   Cortelazzo, Sergio ^h   Rule, Simon ⁱ   Hess, Georg ^j   Zaja, Francesco ^k   Vitolo, Umberto ^l   Szymczyk, Michal ^m   Walewski, Jan ^m   Ribrag, Vincent ⁿ   Unterhalt, Michael ^o   Hermine, Olivier ^o   Hoster, Eva ^a   more..

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^d UNIVERSITY OF WÜRZBURG   (Germany)

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^f INSTITUTE OF EPIDEMIOLOGY   (Germany)

^g Hematology Department Hospital Htel Dieu   (France)

^h CENTRAL HOSPITAL OF BOLZANO   (Italy)

ⁱ DERRIFORD HOSPITAL   (United Kingdom)

^j UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^k UNIVERSITY HOSPITAL OF UDINE   (Italy)

^l MOLINETTE HOSPITAL   (Italy)

^m INSTITUTE OF ONCOLOGY   (Poland)

ⁿ INSTITUT GUSTAVE ROUSSY   (France)

^o HÔPITAL NECKER ENFANTS MALADES   (France)

more..

Author keywords

Clinical treatment; Mantle cell lymphoma

Indexed keywords

BENDAMUSTINE; BORTEZOMIB; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GLUCOSE REGULATED PROTEIN 78; LENALIDOMIDE; MAMMALIAN TARGET OF RAPAMYCIN; MELPHALAN; METHOTREXATE; PREDNISONE; PROTEASOME; PROTEIN KINASE B; RETASPIMYCIN; RITUXIMAB; TEMSIROLIMUS; VINCRISTINE;

ALLOGENEIC STEM CELL TRANSPLANTATION; APOPTOSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CANCER RESISTANCE; CANCER SURVIVAL; DOWN REGULATION; ENDOPLASMIC RETICULUM; GENE EXPRESSION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MAINTENANCE THERAPY; MANTLE CELL LYMPHOMA; PATHOGENESIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

CLINICAL TRIALS AS TOPIC; HUMANS; LYMPHOMA, MANTLE-CELL; PROTEASOME ENDOPEPTIDASE COMPLEX;

EID: 82255184040     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.600488     Document Type: Review

References (28)

1. Dreyling M, Hiddemann W. Current treatment standards and emerging strategies in mantle cell lymphoma. Hematology Am Soc Hematol Educ Program 2009:542-554.
2. Martin P, Chadburn A, Christos P, et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol 2009;27:1209-1213.
3. Fernandez V, Salamero O, Espinet B, et al. Genomic and gene expression prof ling def nes indolent forms of mantle cell lymphoma. Cancer Res 2010;70:1408-1418.
4. Komatsu H, Iida S, Yamamoto K, et al. A variant chromosome translocation at 11q13 identifying PRAD1/cyclin D1 as the BCL-1 gene. Blood 1994;84:1226-1231. (Pubitemid 24245889)
5. Wlodarska I, Meeus P, Stul M, et al. Variant t(2;11)(p11;q13) associated with the IgK-CCND1 rearrangement is a recurrent translocation in leukemic small-cell B-non-Hodgkin lymphoma. Leukemia 2004;18:1705-1710. (Pubitemid 39386351)
6. Espinet B, Salaverria I, Bea S, et al. Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma. Genes Chromosomes Cancer 2010;49:439-451.
7. Martin-Subero JI, Odero MD, Hernandez R, et al. Amplif cation of IGH/MYC fusion in clinically aggressive IGH/BCL2-positive germinal center B-cell lymphomas. Genes Chromosomes Cancer 2005;43:414-423. (Pubitemid 40946476)
8. Zhu C, Mills KD, Ferguson DO, et al. Unrepaired DNA breaks in p53-def cient cells lead to oncogenic gene amplif cation subsequent to translocations. Cell 2002;109:811-821. (Pubitemid 34785997)
9. Salaverria I, Espinet B, Carrio A, et al. Multiple recurrent chromosomal breakpoints in mantle cell lymphoma revealed by a combination of molecular cytogenetic techniques. Genes Chromosomes Cancer 2008;47:1086-1097.
10. Nagel I, Szczepanowski M, Martin-Subero JI, et al. Deregulation of the telomerase reverse transcriptase (TERT) gene by chromosomal translocations in B-cell malignancies. Blood 2010;116:1317-1320.
11. Rosenwald A, Wright G, Wiestner A, et al. Te proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003;3: 185-197. (Pubitemid 37443390)
12. Fu K, Weisenburger DD, Greiner TC, et al. Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression prof ling. Blood 2005;106:4315-4321. (Pubitemid 41775942)
13. Hartmann EM, Campo E, Wright G, et al. Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number prof ling. Blood 2010;116:953-961.
14. Lenz G, Wright GW, Emre NC, et al. Molecular subtypes of dif use large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci USA 2008;105:13520-13525.
15. Zeng Q, Hong W. Te emerging role of the hippo pathway in cell contact inhibition, organ size control, and cancer development in mammals. Cancer Cell 2008;13:188-192. (Pubitemid 351318373)
16. Dreyling M, Lenz G, Hoster E, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission signif cantly prolongs progression-free survival in mantle cell lymphoma-results of a prospective randomized trial of the European MCL Network. Blood 2005;105:2677-2684. (Pubitemid 40450320)
17. Delarue R, Haioun C, Ribrag V, et al. R-CHOP and R-DHAP followed by autologous stem cell transplantation in MCL: f nal rsults of a phase II study from the GELA. Blood 2008;112(Suppl. 1): Abstract 581.
18. Hermine O, Hoster E, Walewski J, et al. Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) is superior to 6 courses CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: results of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net). Blood 2010;116(Suppl. 1): Abstract 110.
19. Pott C, Hoster E, Böttcher S, et al. Molecular remission after combined immunochemotherapy is of prognostic relevance in patients with MCL: results of the randomized intergroup trials of the European MCL Network. Blood 2010;115:3215-3223.
20. Geisler CH, Kolstad A, Laurell A, et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008;112:2687-2693.
21. Kluin-Nelemans JC, Hoster E, Vehling-Kaiser U, et al. Rituximab maintenance signif cantly prolongs duration of remission in elderly patients with mantle cell lymphoma. First results of a randomized trial of the European MCL Network. Haematologica 2011;96(Suppl. 2); Abstract 504.
22. Wiernik PH, Lossos IS, Tuscano JM, et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 2008;26:4952-4957.
23. Habermann TM, Lossos IS, Justice G, et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol 2009;145:344-349.
24. Zaja F, De Luca S, Vitolo U, et al. Salvage treatment with lenalidomide and dexamethasone in patients with relapsed refractory mantle cell lymphoma: clinical results and modif cations of angiogenic biomarkers. Blood 2010;116(Suppl. 1): Abstract 966.
25. Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity prof le in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 2005;23:3383-3389.
26. Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 2008;26:4473-4479.
27. Pedersen L, Laurell A, Elonen E, et al. Successful preemptive treatment of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. Blood 2007;110(Suppl. 1): Abstract 1281.
28. Dreyling M, Hoster E, Bea S, et al. Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma (MCL): minutes of the 9th European MCL Network conference. Leuk Lymphoma 2010;51:1612-1622.